ArticleJournal of medicinal chemistry2026
Development and Biological Characterization of Fluorescent Dynorphins for the Visualization of Kappa Opioid Receptors.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kappa opioid receptor (KOR) controls a wide variety of biological processes, including pain and reward responses. However, its precise spatiotemporal location remains poorly understood due to limited selective molecular tools. We addressed this problem by developing dynorphin-based fluorescent KOR tracers that are selective for KOR over its closely related mu- and delta-family members (MOR, DOR). Our lead tracer is highly selective for KOR (>360-fold over MOR and DOR) and can effectively visualize KORs in the somatodendritic compartment of cultured primary cortical neurons, as well as in superficial layer neurons of the spinal cord dorsal horn. Furthermore, it blocked the KOR agonist U50,488-induced reduction in the excitatory drive of spinal cord neurons. The developed tracer can also be immobilized with paraformaldehyde and used for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.